Home › Lung Diseases › Rhode Island › Providence
Lung Diseases clinical trials in Providence, RI
4 studies for Lung Diseases are looking for participants at sites in and around Providence (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RecruitingPhase 3
- Brown University - Rhode Island Hospital, Providence
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Lifespan Cancer Institute, Providence
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RecruitingPhase 3
- Research Site, Providence
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RecruitingPhase 2
- Clinical Research Site, Providence
About Lung Diseases
Lung diseases are disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. Find out more about prevention, living with lung diseases, and treatment.
More about Lung Diseases on MedlinePlus
Lung Diseases trials in other cities
- Houston, TX16 studies
- Boston, MA14 studies
- Durham, NC13 studies
- New York City, NY13 studies
- Pittsburgh, PA11 studies
- Dallas, TX10 studies
- Los Angeles, CA10 studies
- Ann Arbor, MI10 studies
- Miami, FL10 studies
- Columbus, OH10 studies
- Chicago, IL9 studies
- Washington, DC9 studies
Other studies in Providence
- Ovarian Cancer15 studies
- Obesity14 studies
- Endometrial Cancer14 studies
- Non-Small Cell Lung Cancer13 studies
- Cancer (all types)12 studies
- Acute Myeloid Leukemia11 studies
- Crohn's Disease10 studies
- Ulcerative Colitis10 studies
- Overweight9 studies
- Metastatic Cancer9 studies
- Breast Cancer9 studies
- Alzheimer's Disease9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.